AstraZeneca
1,704.00 SEK
+0.56 %
Less than 1K followers
AZN
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.56 %
+9.20 %
+11.15 %
+22.33 %
+17.80 %
+16.59 %
+19.50 %
+86.68 %
+9,223.96 %
AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.
Read moreMarket cap
2.64T SEK
Turnover
296.64M SEK
Revenue
596.39B
EBIT %
18.5 %
P/E
34.03
Dividend yield-%
2.01 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
10/2
2026
Annual report '25
All
Press releases
ShowingAll content types
AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH
AstraZeneca: Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools